Salmon diet in patients with active ulcerative colitis reduced the simple clinical colitis activity index and increased the anti-inflammatory fatty acid index - A pilot study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 1, 2011, Pages 68-73

  Grimstad, Tore ^a,c   Berge, Rolf K ^b   Bohov, Pavol ^b   Skorve, Jon ^b   Gøransson, Lasse ^a,c   Omdal, Roald ^a,c   Aasprong, Ole G ^a   Haugen, Margaretha ^d   Meltzer, Helle M ^d   Hausken, Trygve ^b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Diet therapy; Fish oils; Inflammatory bowel diseases; Omega 3 fatty acids; Ulcerative colitis

Indexed keywords

ARACHIDONIC ACID; CALGRANULIN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIINFLAMMATORY FATTY ACID INDEX; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; DIET THERAPY; DIETARY INTAKE; ENDOSCOPY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RECTUM BIOPSY; SALMON; SIGMOIDOSCOPY; SIMPLE CLINICAL COLITIS ACTIVITY INDEX; ULCERATIVE COLITIS;

ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DIET; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PILOT PROJECTS; QUESTIONNAIRES; RECTUM; SALMON;

SALMO SALAR;

EID: 78651366691     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.542484     Document Type: Article

References (21)

1. Sands BE. Infl ammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:16-25.
2. Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic infl ammatory bowel disease-a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl 1989;731:225-32.
3. Aslan A, Triadafi lopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 1992;87:432-7.
4. Stenson W. Dietary supplementation with fish oil in ulcerative colitis. Ann Int Med 1992;116:609-14.
5. MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, Hilton LG, Gralnek IM, Rhodes S, Khanna P, Morton SC. Systematic review of the effects of n-3 fatty acids in infl ammatory bowel disease. Am J Clin Nutr 2005;82:611-9.
6. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation. Comparison between young and older women. J Nutr 1991;121:547-55.
7. Tjonneland A, Overvad K, Bergmann MM, Nagel G, Lin-seisen J, Hallmans G, Palmqvist R, Sjodin H, Hagglund G, Berglund G, Lindgren S, Grip O, Palli D, Day NE, Khaw KT, Bingham S, Riboli E, Kennedy H, Hart A. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 2009;58:1606-11.
8. Calder PC. N-3 polyunsaturated fatty acids, infl ammation, and infl ammatory diseases. Am J Clin Nutr 2006;83:1505S-19S.
9. John S, Luben R, Shrestha SS, Welch A, Khaw KT, Hart AR. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol 2010;22:602-6.
10. Visioli F, Rise P, Barassi MC, Marangoni F, Galli C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 2003;38:415-8.
11. Shirai N, Suzuki H, Wada S. Direct methylation from mouse plasma and from liver and brain homogenates. Anal Biochem 2005;343:48-53.
12. Utsunomiya T, Chavali SR, Zhong WW, Forse RA. Effects of sesamin-supplemented dietary fat emulsions on the ex vivo production of lipopolysaccharide-induced prostanoids and tumor necrosis factor alpha in rats. Am J Clin Nutr 2000;72:804-8.
13. Brantsaeter AL, Haugen M, Alexander J, Meltzer HM. Validity of a new food frequency questionnaire for pregnant women in the Norwegian mother and child cohort study (MOBA). Matern Child Nutr 2008;4:28-43.
14. Brantsaeter AL, Haugen M, Hagve TA, Aksnes L, Rasmussen SE, Julshamn K, Alexander J, Meltzer HM. Self-reported dietary supplement use is confi rmed by biological markers in the Norwegian mother and child cohort study (MOBA). Ann Nutr Metab 2007;51:146-54.
15. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29-32.
16. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-6.
17. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with infl ammatory bowel disease. Scand J Gastroenterol 2004; 39:1017-20.
18. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal infl ammation in infl ammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and pmn-elastase, crp, and clinical indices. Am J Gastroenterol 2008;103: 162-9.
19. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of infl ammatory bowel disease. Am J Gastroenterol 2000; 95:359-67.
20. Truelove SC. Medical management of ulcerative colitis and indications for colectomy. In: Jarnerot G, editor. Infl amma-tory bowel disease. Corona AB; 1992:363-76.
21. Almallah YZ, Richardson S, O ' Hanrahan T, Mowat NA, Brunt PW, Sinclair TS, Ewen S, Heys SD, Eremin O. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol 1998;93:804-9.